Trial Profile
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Dabigatran etexilate (Primary) ; Ticagrelor (Primary) ; Aspirin; Warfarin
- Indications Embolism
- Focus Adverse reactions; Registrational
- Acronyms RE-DUAL PCI
- Sponsors Boehringer Ingelheim
- 27 May 2021 Results of sub-analysis assessing the effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation published in the Clinical Cardiology
- 18 Oct 2020 Results of landmark analysis assessing antithrombotic strategies before and after first month of therapy presented at the 32nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 19 Jun 2020 Results published in the Drugs